Literature DB >> 2157514

Prophylaxis against hepatitis A for travel.

P Moore1, P Oakeshott, J Logan, J Law, D M Harris.   

Abstract

OBJECTIVE: To develop a rational practice policy for prophylaxis against hepatitis A for travellers to high risk areas.
DESIGN: 18 Month prospective study of consecutive patients who requested prophylaxis against hepatitis A.
SETTING: Inner city general practice.
SUBJECTS: 104 Patients aged 15-61 (mean 30) assessed for risk factors for hepatitis A and put into groups depending on predictions from the risk factors of their immunity. MAIN OUTCOME MEASURES AND
RESULTS: All patients were screened for antibody to hepatitis A virus. Of 52 patients with no risk factors 47 had no antibody and were thus susceptible to hepatitis A. All 27 patients with major risk factors (having been brought up in an endemic area or with a history of jaundice) were immune. Of 25 patients with minor risk factors (a history of previous travel in high risk areas, drug abuse, having lived in a squat or travelled rough, or having lived with someone who had jaundice) 12 were immune (p less than 0.001, chi 2 test).
CONCLUSIONS: All travellers requesting prophylaxis against hepatitis A should be assessed for risk factors for previous exposure to hepatitis A. Those with no risk factors could be immunised with human normal immunoglobulin without screening. The remainder should be tested for hepatitis A antibody and those found to be susceptible should be immunised.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157514      PMCID: PMC1662508          DOI: 10.1136/bmj.300.6726.723

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  5 in total

1.  Not all travellers need immunoglobulin for hepatitis A.

Authors:  J H Cossar; D Reid
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

2.  Hepatitis A antibodies in London blood donors, medical students, and patients.

Authors:  J E Banatvala; R J Thorogood
Journal:  Lancet       Date:  1980-03-15       Impact factor: 79.321

3.  Rational programme for screening travellers for antibodies to hepatitis A virus.

Authors:  J V Parry; C P Farrington; K R Perry; P A Waight; P P Mortimer; E Miller
Journal:  Lancet       Date:  1988-06-25       Impact factor: 79.321

4.  Not all travellers need immunoglobulin for hepatitis A.

Authors:  G Kudesia; E A Follett
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-11

5.  Hepatitis prophylaxis for travellers.

Authors:  P G Hill; T J John
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

  5 in total
  4 in total

1.  An outbreak of hepatitis A in Gloucester, UK.

Authors:  F A Majeed; J M Stuart; K A Cartwright; R Room; J R Gilkes; M C Smith; B E Watson
Journal:  Epidemiol Infect       Date:  1992-08       Impact factor: 2.451

Review 2.  Tropical medicine.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

3.  The prevalence and direct costs of pre-immunization testing for hepatitis A in general practice.

Authors:  D Buckley; T Fahey; G Bevan
Journal:  Br J Gen Pract       Date:  1996-09       Impact factor: 5.386

4.  Prophylaxis against hepatitis A for travel.

Authors:  K R Neal; E M Dunbar
Journal:  BMJ       Date:  1990-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.